FNOS NEWSLETTER

Issue 3 November 2001

The ENOS acronym stands for "Efficacy of Nitric Oxide in Stroke". This study is a collaborative, international, multicentre, prospective, randomised, open, blinded-endpoint, parallel group, controlled, trial to investigate the safety and efficacy of treatment with transdermal glyceryl trinitrate, a nitric oxide donor, and of continuing or stopping prior antihypertensive therapy, in patients with acute ischaemic or haemorrhagic stroke. A summary of the study protocol can be found at www.nottingham.ac.uk/stroke-medicine/enosindex.htm. If you would like to receive an up to date version of the full trial protocol then please email us at enos@nottingham.ac.uk.

The Web Site

For maximum efficiency the ENOS trial will be conducted over a secure internet site. This site will provide access for downloadable documents, emails, and web-based randomisation, data registration and a conduit for reporting serious adverse events. A beta version of the trial website is now available for interested sites to log onto. If you would like to try it out go to www.nottingham.ac.uk/stroke-medicine/enosindex.htm. Enter the username Yeung001 and the password Yeung001 (the software is case sensitive). Next enter the pin number 0010 and you should gain access. Please feel free to explore the site and try completing the ENOS case report forms (there is no 'real' patient data present on this site). Your comments will be much appreciated. The final version of the site is still a few weeks away from completion. Entry to this will be restricted and individual passwords will be required in order to gain access.

Progress

We are pleased to announce that our first international site in Singapore has completed its application process and has approval to run the trial. We would welcome other interested sites and ask them to fax or post the form which is attached with this newsletter to the ENOS trial office. Alternatively, you can access the form at www.nottingham.ac.uk/stroke-medicine/enosindex.htm.

For an interim period and until we have a final version of the website we will be running the trial on paper. The relevant documentation will shortly be downloadable for this purpose and completed forms should be faxed to the ENOS trial coordinating centre for entry into the trial database.

Since our last newsletter we now have a total of 13 patients randomised into ENOS.